Company Interpace Biosciences, Inc.

Stocks

IDXGD

US46062X4025

Healthcare Facilities & Services

Market Closed - OTC Markets 15:05:06 2026-09-18 EDT			5-day change	1st Jan Change
6.450 ^USD	0.00%		-0.77%	+4.86%

08-10	Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-12	Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Business description: Interpace Biosciences, Inc.

Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Companyâ€™s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physiciansâ€™ better risk-stratify pancreaticobiliary cancers using the Companyâ€™s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.

Number of employees: 102

Sales by Activity: Interpace Biosciences, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Developing and Selling Clinical and Pharma Services	41.31M	31.84M	40.21M	46.93M	38.73M

See all business segments

Geographical breakdown of sales: Interpace Biosciences, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
United States	41.31M	31.84M	40.21M	46.93M	38.73M

See all geographic segments

Executive Committee: Interpace Biosciences, Inc.

Manager	Title	Age	Since
Thomas Burnell CEO	Chief Executive Officer	64	2020-11-30
Christopher McCarthy DFI	Director of Finance/CFO	34	2023-04-20
Nicole Massoll CTO	Chief Tech/Sci/R&D Officer	-	-
Sydney Finkelstein CTO	Chief Tech/Sci/R&D Officer	-	-

See INTERPACE BIOSCIENCES, INC. governance

Composition of the Board of Directors: Interpace Biosciences, Inc.

Director	Title	Age	Since
Stephen Sullivan CHM	Chairman	79	2016-06-20
Joseph Keegan BRD	Director/Board Member	73	2015-12-31
Fortunato Rocca BRD	Director/Board Member	64	2020-01-21
Thomas Burnell CHM	Chairman	64	-
Vijay Aggarwal BRD	Director/Board Member	77	2022-01-31

Composition of the Board of Directors

Shareholders: Interpace Biosciences, Inc.

Name	Stocks	%	Valuation
Ampersand Management LLC 47.21 %	2,772,277	47.21 %	21 M $
1315 Capital LLC 32.03 %	1,881,188	32.03 %	14 M $
Thomas Burnell 4.995 %	293,362	4.995 %	2 M $
Christopher McCarthy 1.103 %	64,760	1.103 %	490 233 $
Stephen Sullivan 0.008378 %	492	0.008378 %	3 724 $

List of INTERPACE BIOSCIENCES, INC. shareholders

Company details: Interpace Biosciences, Inc.

Interpace Biosciences, Inc.

Waterview Plaza

07054, Parsippany

+855 776 6419

http://www.interpace.com

address Interpace Biosciences, Inc.(IDXGD)

Medical & Diagnostic Laboratories

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTERPACE BIOSCIENCES, INC.	0.00%	-0.77%	+57.32%	+12.17%	35.73M
NATERA, INC.	+0.84%	+12.30%	+105.38%	+623.44%	52.8B
LABCORP HOLDINGS INC.	-0.63%	+2.94%	+15.72%	+59.42%	26.17B
SONIC HEALTHCARE LIMITED	-1.94%	+1.26%	-13.10%	-37.94%	6.89B
RADNET, INC.	-2.29%	+0.68%	-0.76%	+171.23%	6.12B
DR. LAL PATHLABS LIMITED	-1.44%	-0.63%	+15.47%	+60.65%	3.36B
GENEDX HOLDINGS CORP.	-3.67%	+18.57%	-22.65%	+2,433.83%	3.13B
NEOGENOMICS, INC.	+0.10%	+14.95%	+130.97%	+52.22%	2.56B
FLEURY S.A.	+14.45%	-0.09%	+33.88%	+46.34%	2.26B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	+3.13%	+8.10%	-10.08%	-54.93%	1.85B
Average	+0.86%	+5.27%	+31.21%	+336.64%	10.52B
Weighted average by Cap.	+0.22%	+8.01%	+59.48%	+410.90%